- Home
- PRG vs XERS Comparison
PRG vs XERS Comparison
Compare PRG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | XERS |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRG | XERS |
|---|---|---|
| Price | $39.49 | $8.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $50.00 | $10.83 |
| AVG Volume (30 Days) | 431.0K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,409,223,000.00 | $49,590,000.00 |
| Revenue This Year | $23.77 | $34.37 |
| Revenue Next Year | $7.91 | $22.86 |
| P/E Ratio | $21.51 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $25.80 | $5.25 |
| 52 Week High | $47.73 | $10.08 |
Technical Indicators
Market Signals| Indicator | PRG | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 58.40 |
| Support Level | $38.13 | $7.06 |
| Resistance Level | $41.14 | $9.01 |
| Average True Range (ATR) | 1.15 | 0.29 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 26.57 | 65.18 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.